CureVac: Perbedaan antara revisi
Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.8.7 |
Wagino Bot (bicara | kontrib) k →Pranala luar: Bot: Merapikan artikel |
||
| (2 revisi perantara oleh 2 pengguna tidak ditampilkan) | |||
| Baris 5: | Baris 5: | ||
| traded_as = {{Nasdaq|CVAC}} |
| traded_as = {{Nasdaq|CVAC}} |
||
| founded = 2000 |
| founded = 2000 |
||
| founders = [[Ingmar Hoerr]],<ref name="founder">{{cite press release |title=CureVac Announces New Management Structure |url=http://www.curevac.com/news/curevac-announces-new-management-structure/ |publisher=Curevac |language=en }} {{ |
| founders = [[Ingmar Hoerr]],<ref name="founder">{{cite press release |title=CureVac Announces New Management Structure |url=http://www.curevac.com/news/curevac-announces-new-management-structure/ |publisher=Curevac |language=en }} {{Cite web |url=http://www.curevac.com/news/curevac-announces-new-management-structure/ |title=Salinan arsip |access-date=2020-12-03 |archive-date=2018-06-21 |archive-url=https://web.archive.org/web/20180621194048/http://www.curevac.com/news/curevac-announces-new-management-structure/ |dead-url=unfit }}</ref> Steve Pascolo, Florian von der Muelbe, Günther Jung and Hans-Georg Rammensee |
||
| location = [[Tübingen]], [[Jerman]] |
| location = [[Tübingen]], [[Jerman]] |
||
| num_employees = > 450<ref name="Official Website - Company">{{cite web|url=http://www.curevac.com/company|title=Company Information|date=|website=Curevac}}</ref> |
| num_employees = > 450<ref name="Official Website - Company">{{cite web|url=http://www.curevac.com/company|title=Company Information|date=|website=Curevac}}</ref> |
||
| Baris 31: | Baris 31: | ||
*{{official|http://www.curevac.com }} |
*{{official|http://www.curevac.com }} |
||
{{authority control}} |
{{authority control}} |
||
[[Kategori:Tübingen]] |
[[Kategori:Tübingen]] |
||
{{perusahaan-stub}} |
|||
Revisi terkini sejak 1 September 2023 07.39
 | |
| N.V. | |
| Kode emiten | Nasdaq: CVAC |
| Industri | Bioteknologi |
| Didirikan | 2000 |
| Pendiri | Ingmar Hoerr,[1] Steve Pascolo, Florian von der Muelbe, Günther Jung and Hans-Georg Rammensee |
| Kantor pusat | Tübingen, Jerman |
Tokoh kunci | Dr. Franz-Werner Haas (CEO) |
| Total ekuitas |
|
Karyawan | > 450[2] |
| Situs web | www |
CureVac N.V. adalah sebuah perusahaan biofarmasi yang bermarkas besar di Tübingen, Jerman, yang mengembangkan terapi-terapi yang berdasarkan pada RNA duta (mRNA). Fokus perusahaan tersebut adalah untuk mengembangkan vaksin untuk penyakit menular dan obat-obatan untuk mengobati kanker dan penyakit langka. Didirikan pada 2000 oleh Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Gunther Jung dan Hans-Georg Rammensee, CureVac memiliki sekitar 240 karyawan pada November 2015[3] and 375 in May 2018.[2]
CureVac masuk dalam berbagai kolaborasi dengan organisasi-organisasi, yang meliputi perjanjian-perjanjian dengan Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline,[4][5] Coalition for Epidemic Preparedness Innovations, dan International AIDS Vaccine Initiative.[6]
Lihat pula[sunting | sunting sumber]
Referensi[sunting | sunting sumber]
- ^ "CureVac Announces New Management Structure" (Siaran pers) (dalam bahasa Inggris). Curevac. "Salinan arsip". Archived from the original on 2018-06-21. Diakses tanggal 2020-12-03.
- ^ a b "Company Information". Curevac.
- ^ "Gates, Hopp back $110M megaround for CureVac's mRNA work".
- ^ Carroll, John (18 October 2017). "Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines". endpts.com.
- ^ Aripaka, Pushkala; Schuetze, Arno (19 July 2020). "GSK buys 10% of CureVac in vaccine tech deal". Reuters. Diakses tanggal 21 July 2020.
- ^ "CureVac Opens up an mRNA Hub in Moderna's Cambridge Backyard". 10 September 2015.
Pranala luar[sunting | sunting sumber]
Media terkait Curevac di Wikimedia Commons
 | Artikel bertopik perusahaan ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya. |